| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3113141 | Medicina Intensiva | 2007 | 11 Pages |
Abstract
Use of GPIIb/IIIa inhibitors reduces the risk of adverse cardiac events in NSTEACS patients pre-treated with aspirin and thienopyridines but increases the risk of severe bleeding and thrombocytopenia. Its utilization in stable coronary patients does not seem justified.
Keywords
Revascularización percutáneanon-ST segment elevation acute coronary syndromeEptifibatideAnginaAngioplastia coronáriaCoronary angioplastyInfarto de miocardioMyocardial ischemiaIsquemia miocárdicaSupervivenciaSurvivalTirofibanThienopyridinesTiclopidineAbciximabpercutaneous revascularizationclopidogrel
Related Topics
Health Sciences
Medicine and Dentistry
Critical Care and Intensive Care Medicine
Authors
J. Latour-Pérez, E. De Miguel-Balsa, A. Alcalá-López, F.J. Coves-Orts,